Study #2021-0057
A phase II trial of sitravatinib plus nivolumab in patients with metastatic clear cell renal cell carcinoma who progressed on prior treatment Acronym: SNAPI (Sitravatinib and Nivolumab After Prior Immunotherapy)
MD Anderson Study Status
Not Accepting
Treatment Agent
Nivolumab, Sitravatinib
Description
This phase II trial investigates the effect of sitravatinib and nivolumab in treating patients with clear cell renal cell cancer that has spread to other places in the body (metastatic/advanced). Sitravatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving sitravatinib and nivolumab may kill more tumor cells.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Study phase:
Phase II
Physician name:
Pavlos Msaouel
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-866-967-2182
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.